GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-7.63%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$388M
AUM Growth
+$388M
(-6.1%)
Cap. Flow
+$5.08M
Cap. Flow
% of AUM
1.31%
Top 10 Holdings %
Top 10 Hldgs %
56.11%
Holding
41
New
11
Increased
11
Reduced
7
Closed
7
Top Buys
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$18.9M |
| 2 |
Sarepta Therapeutics
SRPT
|
$14.5M |
| 3 |
Nektar Therapeutics
NKTR
|
$12M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$11.1M |
| 5 |
Alkermes
ALKS
|
$10.8M |
Top Sells
| 1 |
Exelixis
EXEL
|
$29.5M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
$24.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$22.2M |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$19M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLN
26
Silence Therapeutics
SLN
$227M
| $4.76M | 1.14% | 401,449 -42,994 | -10% | -$509K |
|
|
PVLA
27
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $4.7M | 1.13% | 2,512,500 +313,424 | +14% | +$586K |
|
|
ALPN
28
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $4.59M | 1.1% | +538,819 | New | +$4.59M |
|
29
89bio
ETNB
$1.34B
| $4.51M | 1.08% | +1,400,000 | New | +$4.51M |
|
30
Pliant Therapeutics
PLRX
$101M
| $2.86M | 0.69% | +357,263 | New | +$2.86M |
|
31
MoonLake Immunotherapeutics
MLTX
$3.54B
| $2.27M | 0.54% | +432,000 | New | +$2.27M |
|
32
Dianthus Therapeutics
DNTH
$759M
| $1.4M | 0.34% | 1,170,000 | – | – |
|
33
Spyre Therapeutics
SYRE
$996M
| $1.26M | 0.3% | +2,500,000 | New | +$1.26M |
|
34
Alnylam Pharmaceuticals
ALNY
$58.5B
| – | – | 0 | – | – |
|
35
Ardelyx
ARDX
$1.53B
| – | – | -4,761,905 | Closed | -$5.1M |
|
|
BCYC
36
Bicycle Therapeutics
BCYC
$511M
| – | – | -550,592 | Closed | -$24.2M |
|
|
37
Exelixis
EXEL
$10.1B
| – | – | -1,300,000 | Closed | -$29.5M |
|
38
Passage Bio
PASG
$22.7M
| – | – | -113,900 | Closed | -$353K |
|
39
Rafael Holdings
RFL
$51.6M
| – | – | -121,000 | Closed | -$304K |
|
|
40
Rigel Pharmaceuticals
RIGL
$697M
| – | – | -4,000,000 | Closed | -$12M |
|
|
41
Vertex Pharmaceuticals
VRTX
$100B
| – | – | -85,000 | Closed | -$22.2M |
|